{"disease":{"id":"neisseria-meningitidis","name":"Neisseria Meningitidis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":2,"trial_count":1},"drugs":{"marketed":[{"drug_id":"benzylpenicillin","indication_name":"Upper Respiratory Infection due to Neisseria Meningitidis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"merrem","indication_name":"Neisseria meningitidis meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Merrem","company_name":"National Institutes of Health Clinical Center (CC)","drug_phase":"marketed","molecular_target":"Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"meropenem","indication_name":"Neisseria meningitidis meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Merrem","generic_name":"Meropenem","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"meropenem","quality_score":10,"revenue":null,"mechanism":"Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"penicillin","indication_name":"Upper Respiratory Infection due to Neisseria Meningitidis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"penbraya","indication_name":"Neisseria Meningitidis","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PENBRAYA","generic_name":"penbraya","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. ","quality_score":0,"revenue":null,"mechanism":"PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. "},{"drug_id":"trumenba","indication_name":"Neisseria Meningitidis","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trumenba","generic_name":"trumenba","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains","quality_score":0,"revenue":null,"mechanism":"Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains"}],"offLabel":[],"totalMarketed":4,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT03419533","title":"Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers","phase":"","overall_status":"COMPLETED","enrollment_count":6802,"lead_sponsor_name":"University of Adelaide","has_results":true},{"nct_id":"NCT00289783","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4441,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00134719","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1104,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00228917","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":798,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00129129","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":756,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00136604","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":617,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01978093","title":"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00891176","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":582,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01090453","title":"Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00326118","title":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":433,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00127855","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":409,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00129116","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01839188","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT00586612","title":"Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00454987","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00871338","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":284,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01553279","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":284,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT07395739","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","has_results":false},{"nct_id":"NCT00871741","title":"Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}